Selected Publications
Emerging Viruses and Infectious Diseases
Belem WF, Liu CH, Hu YT, Burnouf T, Lin LT*. Validation of Viral Inactivation Protocols for Therapeutic Blood Products against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-COV-2). Viruses. 2022 Oct 31;14(11):2419.
Liu CH, Lu CH, Lin LT*. Pandemic Strategies with Computational and Structural Biology against COVID-19: A Retrospective. Comput Struct Biotechnol J. 2021 Dec 5;20:187-92.
Kuo YT, Liu CH, Corona A, Fanunza E, Tramontano E, Lin LT*. The Methanolic Extract of Perilla frutescens Robustly Restricts Ebola Virus Glycoprotein-Mediated Entry. Viruses. 2021 Sep 8;13(9):1793.
Kwan JYY, Lin LT*, Bell R, Bruce JP, Richardson C, Pugh TJ, Liu FF. Elevation in viral entry genes and innate immunity compromise underlying increased infectivity and severity of COVID-19 in cancer patients. Sci Rep. 2021 Feb 25;11(1):4533.
Liu CH, Lu CH, Wong SH, Lin LT*. Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects. Front Immunol. 2021 Feb 5;11:616595.
Kuo YT, Liu CH, Li JW, Lin CJ, Jassey A, Wu HN, Perng GC, Yen MH, Lin LT*. Identification of the phytobioactive Polygonum cuspidatum as an antiviral source for restricting dengue virus entry. Sci Rep. 2020 Oct 2;10(1):16378.
Liu CH, Grandi N, Palanivelu L, Tramontano E, Lin LT*. Contribution of Human Retroviruses to Disease Development-A Focus on the HIV- and HERV-Cancer Relationships and Treatment Strategies. Viruses. 2020 Aug 4;12(8):852.
Wong SH, Jassey A, Wang JY, Wang WC, Liu CH, Lin LT*. Virus-Like Particle Systems for Vaccine Development against Viruses in the Flaviviridae Family. Vaccines (Basel). 2019 Sep 20;7(4):123.
Jassey A, Liu CH, Changou CA, Richardson CD, Hsu HY, Lin LT*. Hepatitis C Virus Non-Structural Protein 5A (NS5A) Disrupts Mitochondrial Dynamics and Induces Mitophagy. Cells. 2019 Mar 29;8(4). pii: E290.
Lin CJ, Liu CH, Wang JY, Lin CC, Li YF, Richardson CD, Lin LT*. Small molecules targeting coxsackievirus A16 capsid inactivate viral particles and prevent viral binding. Emerg Microbes Infect. 2018; 7: 162.
Liu CH, Lin CC, Hsu WC, Chung CY, Lin CC, Jassey A, Chang SP, Tai CJ, Tai CJ, Shields J, Richardson CD, Yen MH, Tyrrell DL, Lin LT*. Highly Bioavailable silibinin nanoparticles inhibit HCV infection. Gut. 2017 Oct ;66(10):1853-1861.
Chung CY, Liu CH, Wang GH, Jassey A, Li CL, Chen L, Yen MH, Lin CC, Lin LT*. (4R, 6S)-2-Dihydromenisdaurilide is a Butenolide that Efficiently Inhibits Hepatitis C Virus Entry. Sci Rep. 2016 Jul 18;6:29969.
Lin LT*, Chung CY, Hsu WC, Chang SP, Hung TC, Shields J, Russell RS, Lin CC, Li CF, Yen MH, Tyrrell DL, Lin CC, Richardson CD. Saikosaponin b2 is a Naturally Occurring Terpenoid That Efficiently Inhibits Hepatitis C Virus Entry. J Hepatol. 2015 Mar;62(3):541-8.
Oncolytic Viro-Immunotherapy
Palanivelu L, Liu CH, Lin LT*. Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy. Front Immunol. 2023 Jan 23;13:1038226.
Kuo YT, Liu CH, Wong SH, Pan YC, Lin LT*. Small molecules baicalein and cinnamaldehyde are potentiators of measles virus-induced breast cancer oncolysis. Phytomedicine. 2021 Aug;89:153611.
Liu CH, Wong SH, Tai CJ, Tai CJ, Pan YC, Hsu HY, Richardson CD, Lin LT*. Acid and Its Nanoparticles Are Potentiators of Oncolytic Measles Virotherapy against Breast Cancer Cells. Cancers (Basel). 2021 Jan 4;13(1):136.
Tai CJ, Liu CH, Pan YC, Wong SH, Tai CJ, Richardson CD, Lin LT*. Chemovirotherapeutic Treatment Using Camptothecin Enhances Oncolytic Measles Virus-Mediated Killing of Breast Cancer Cells. Sci Rep. 2019 May 1;9(1):6767.
Lin LT*, Richardson CD. The Host Cell Receptors for Measles Virus and Their Interaction with the Viral Hemagglutinin (H) Protein. Viruses. 2016 Sep 20;8(9). pii: E250.
Noyce RS, Bondre DG, Ha MN, Lin LT*, Sisson G, Tsao MS, Richardson CD. Tumor Cell Marker PVRL4 (Nectin 4) Is an Epithelial Cell Receptor for Measles Virus. PLoS Pathog. 2011 Aug 25;7(8).
Public Engagement
Lin LT*. Emerging Viral Infectious Diseases & Oncolytic Viro-Immunotherapy. Impact. 2018 Dec:10(2018):48-50.